Naropin (ropivacaine hydrochloride Injection, USP), 0.5%
Recalled by Fresenius Kabi USA, LLC
Class II — moderate
Using this product might cause a temporary or medically reversible health problem. The chance of serious harm is low.
Fresenius Kabi USA, LLC has recalled Naropin (ropivacaine hydrochloride Injection, USP), 0.5%, according to data published by the U.S. Food and Drug Administration (FDA). The recall was reported on July 29, 2026 and was initiated on July 16, 2026. It is classified as a Class II recall, which means using this product might cause a temporary or medically reversible health problem. The chance of serious harm is low.
Below is a plain-English summary of what was recalled, why it was recalled, how to tell whether you have the affected product, and what steps you can take. For the complete and most current details, you can view the FDA record linked further down this page.
What was recalled?
This recall covers Naropin (ropivacaine hydrochloride Injection, USP), 0.5%, with approximately 92,600 vials affected. The company behind the recall is Fresenius Kabi USA, LLC, based in Lake Zurich, IL. The FDA describes the product as: “Naropin (ropivacaine hydrochloride Injection, USP), 0.5%, 100 mg per 20 mL (5 mg per mL), Twenty-five, 20 mL Single-Dose Vials, Rx only, Fresenius Kabi, Lake Zurich, IL 60047 NDC Tray: 63323-286-23; NDC Vial: 63323-286-05”
Why was Naropin (ropivacaine hydrochloride Injection, USP), 0.5% recalled?
According to the FDA, the stated reason for the recall is: “Presence of Particulate Matter: Hair was found in products.” In plain terms, this recall relates to a sterility or contamination concern.
Sterile medicines, such as injectables and eye drops, must be completely free of microorganisms and stray particles. This recall means that sterility could not be assured or that contamination was found or suspected. Using a non-sterile product of this kind can cause infections, which is why these recalls are treated seriously.
What should you do?
If you think you may have bought Naropin (ropivacaine hydrochloride Injection, USP), 0.5%, compare it against the product description and identifying codes (Lot #: 6133436, Exp. Date 10/2028) before using it. This recall is currently listed as ongoing.
The general guidance for a matching product is to stop using it and follow the instructions in the official FDA recall notice, which may include a repair, replacement, refund, or safe disposal. When in doubt, contact Fresenius Kabi USA, LLC or your local health authority.
About this recall
This recall was distributed in IL. RecallRadar summarizes recall information from public FDA data to make it easier to understand. We are an independent service and are not affiliated with the FDA or any government agency, so please always refer to the official source for the authoritative record — and note the “last synced” date shown on this page, since recall details can change over time.
Who this recall affects
This recall matters to anyone who bought Naropin (ropivacaine hydrochloride Injection, USP), 0.5%. Even if you feel fine, it's worth checking what you have on hand rather than assuming you were missed.
Distribution listed in the notice: Nationwide within in the USA.
What sterility or contamination concern actually means
Sterile medicines, such as injectables and eye drops, must be completely free of microorganisms and stray particles. This recall means that sterility could not be assured or that contamination was found or suspected. Using a non-sterile product of this kind can cause infections, which is why these recalls are treated seriously.
In this case, the concern applies specifically to Naropin (ropivacaine hydrochloride Injection, USP), 0.5% from Fresenius Kabi USA, LLC — not to the wider category of products. Similar items from other brands aren't part of this recall.
How to check whether you have it
On medicine bottles, the lot number and expiration date are printed on the pharmacy label or stamped directly on the manufacturer's bottle — often near the bottom edge or on the back. If a pharmacy label covers it, your pharmacist can look up the lot they dispensed.
Compare what you find against the identifying details in this recall: Lot #: 6133436, Exp. Date 10/2028
What to do if you already bought it
Do not stop taking a prescribed medicine on your own because of a recall — for many conditions, an interrupted dose carries its own risk.
Instead, check the lot number against the details above and contact your pharmacist, who can confirm what they dispensed and arrange a replacement.
If you've had an unexpected reaction, contact your healthcare provider. Problems can also be reported to the FDA's MedWatch program.
Full recall details
- Status
- Ongoing
- Date reported
- July 29, 2026
- Recall started
- July 16, 2026
- Distributed in
- IL
What you can do
Check whether any product you have matches the description and codes above. If it does, stop using it and follow the instructions in the official recall notice. When in doubt, contact the company or your local health authority.
Quick answers
Why was Naropin (ropivacaine hydrochloride Injection, USP), 0.5% recalled?+
According to the FDA: Presence of Particulate Matter: Hair was found in products
How serious is this recall?+
Class II — moderate. Using this product might cause a temporary or medically reversible health problem. The chance of serious harm is low.
What should I do if I have Naropin (ropivacaine hydrochloride Injection, USP), 0.5%?+
Compare your product against the description and identifying codes on this page. If it matches, stop using it and follow the instructions in the official recall notice — this usually means returning it for a refund or discarding it. When in doubt, contact the company or your local health authority.
Opens the U.S. Food and Drug Administration (FDA) data for this recall.
Recall number: D-0727-2026. Information last synced from the FDA on August 3, 2026.
